Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-02-26 | ENANTA PHARMACEUTICALS INC | Gardiner Nathanie...
(Chief Legal Officer) |
M | Common Stock | A | 5187 | $8.99 - $8.99 | $46,631 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Luu Brendan
(Chief Business Officer) |
F | Common Stock | D | 973 | $12.41 - $12.41 | $12,074 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Luu Brendan
(Chief Business Officer) |
A | Common Stock | A | 3320 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn
(Chief Product Strategy Officer) |
F | Common Stock | D | 973 | $12.41 - $12.41 | $12,074 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn
(Chief Product Strategy Officer) |
A | Common Stock | A | 3320 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Gardiner Nathanie...
(Chief Legal Officer) |
F | Common Stock | D | 973 | $12.41 - $12.41 | $12,074 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Gardiner Nathanie...
(Chief Legal Officer) |
A | Common Stock | A | 3320 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Rottinghaus Scott T.
(Chief Medical Officer) |
F | Common Stock | D | 755 | $12.41 - $12.41 | $9,369 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Rottinghaus Scott T.
(Chief Medical Officer) |
A | Common Stock | A | 2576 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Or Yat Sun
(Chief Scientific Officer) |
F | Common Stock | D | 1080 | $12.41 - $12.41 | $13,402 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Or Yat Sun
(Chief Scientific Officer) |
A | Common Stock | A | 3680 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | MELLETT PAUL J
(Chief Fin. & Admin Officer) |
F | Common Stock | D | 973 | $12.41 - $12.41 | $12,074 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | MELLETT PAUL J
(Chief Fin. & Admin Officer) |
A | Common Stock | A | 3320 | $0.00 - $0.00 | $0 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Luly Jay R.
(President and CEO) |
F | Common Stock | D | 1584 | $12.41 - $12.41 | $19,657 |
2024-02-12 | ENANTA PHARMACEUTICALS INC | Luly Jay R.
(President and CEO) |
A | Common Stock | A | 5400 | $0.00 - $0.00 | $0 |
2023-12-13 | ENANTA PHARMACEUTICALS INC | Vance Terry
(Director) |
S | Common Stock | D | 15295 | $9.12 - $9.12 | $139,490 |
2023-12-05 | ENANTA PHARMACEUTICALS INC | Rottinghaus Scott T.
(Sr. VP & CMO) |
S | Common Stock | D | 534 | $9.63 - $9.63 | $5,142 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |